XML 56 R38.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue from contracts with customers (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Summary of disaggregates revenues by major revenue streams | The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. In conjunction with a recent shift in executive management responsibilities and in alignment with Teva’s Pivot to Growth strategy, Teva decided that Canada is no longer included as part of Teva’s North America segment as of January 1, 2024. From that date Canada is reported as part of the Company’s International Markets segment and Teva’s North America segment has been renamed the United States segment. Teva aligned its internal financial and segment reporting and its reporting units in accordance with this change effective January 1, 2024. Prior period amounts have been recast to conform to the reporting structure for the current year.
|  | Year ended December 31, 2024 |
|  | United states |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 6,327 |  |  |  | 4,891 |  |  |  | 2,280 |  |  |  | 933 |  |  |  | 14,430 |
Licensing arrangements |  |  | 103 |  |  |  | 35 |  |  |  | 24 |  |  |  | 11 |  |  |  | 173 |
Distribution |  |  | 1,536 |  |  |  | 1 |  |  |  | 39 |  |  |  | — |  |  |  | 1,576 |
Other* |  |  | 68 |  |  |  | 176 |  |  |  | 121 |  |  |  | § |  |  |  | 365 |
|  | $ | 8,034 |  |  | $ | 5,103 |  |  | $ | 2,463 |  |  | $ | 944 |  |  | $ | 16,544 |
* | “Other” revenues in all segments include revenues related to sales of certain product rights.
§ | Represents an amount less than $0.5 million.
|  | Year ended December 31, 2023 |
|  | United states |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 5,554 |  |  |  | 4,631 |  |  |  | 2,229 |  |  |  | 565 |  |  |  | 12,979 |
Licensing arrangements * |  |  | 597 |  |  |  | 51 |  |  |  | 28 |  |  |  | 5 |  |  |  | 681 |
Distribution |  |  | 1,577 |  |  |  | § |  |  |  | 38 |  |  |  | — |  |  |  | 1,615 |
Other** |  |  | 2 |  |  |  | 155 |  |  |  | 57 |  |  |  | 357 |  |  |  | 570 |
|  | $ | 7,731 |  |  | $ | 4,837 |  |  | $ | 2,351 |  |  | $ | 926 |  |  | $ | 15,846 |
* | Revenues from licensing arrangements in United states segment were mainly comprised of $500 million upfront payment received in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.
** | “Other” revenues in Europe segment mainly related to the sale of certain product rights.
§ | Represents an amount less than $0.5 million.
|  | Year ended December 31, 2022 |
|  | United states |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 5,383 |  |  |  | 4,455 |  |  |  | 2,257 |  |  |  | 671 |  |  |  | 12,766 |
Licensing arrangements |  |  | 136 |  |  |  | 51 |  |  |  | 22 |  |  |  | 4 |  |  |  | 212 |
Distribution |  |  | 1,471 |  |  |  | 1 |  |  |  | 46 |  |  |  | — |  |  |  | 1,519 |
Other |  |  | 13 |  |  |  | 18 |  |  |  | 27 |  |  |  | 370 |  |  |  | 428 |
|  | $ | 7,003 |  |  | $ | 4,525 |  |  | $ | 2,352 |  |  | $ | 1,045 |  |  | $ | 14,925 |
Summary of Sales Reserves and Allowances |
|  | Sales Reserves and Allowances |
|  | Reserves included in Accounts Receivable, net |  |  | Rebates |  |  | Medicaid and other governmental allowances |  |  | Chargebacks |  |  | Returns |  |  | Other |  |  | Total reserves included in Sales Reserves and Allowances |  |  | Total |
|  | (U.S.$ in millions) |
Balance at January 1, 2024 |  | $ | 61 |  |  |  | 1,603 |  |  |  | 540 |  |  |  | 859 |  |  |  | 436 |  |  |  | 97 |  |  | $ | 3,535 |  |  | $ | 3,596 |
Provisions related to sales made in current year period |  |  | 390 |  |  |  | 4,640 |  |  |  | 787 |  |  |  | 7,952 |  |  |  | 276 |  |  |  | 149 |  |  |  | 13,804 |  |  |  | 14,194 |
Provisions related to sales made in prior periods |  |  | — |  |  |  | 5 |  |  |  | 22 |  |  |  | (11 | ) |  |  | (22 | ) |  |  | (3 | ) |  |  | (9 | ) |  |  | (9 | )
Credits and payments |  |  | (395 | ) |  |  | (4,531 | ) |  |  | (781 | ) |  |  | (7,851 | ) |  |  | (286 | ) |  |  | (126 | ) |  |  | (13,575 | ) |  |  | (13,970 | )
Translation differences |  |  | — |  |  |  | (43 | ) |  |  | (7 | ) |  |  | (13 | ) |  |  | (5 | ) |  |  | (9 | ) |  |  | (77 | ) |  |  | (77 | )
Balance at December 31, 2024 |  | $ | 56 |  |  | $ | 1,674 |  |  | $ | 561 |  |  | $ | 936 |  |  | $ | 399 |  |  | $ | 108 |  |  | $ | 3,678 |  |  | $ | 3,734 |
|  | Sales Reserves and Allowances |
|  | Reserves included in Accounts Receivable, net |  |  | Rebates |  |  | Medicaid and other governmental allowances |  |  | Chargebacks |  |  | Returns |  |  | Other |  |  | Total reserves included in Sales Reserves and Allowances |  |  | Total |
|  | (U.S.$ in millions) |
Balance at January 1, 2023 |  | $ | 67 |  |  | $ | 1,575 |  |  | $ | 663 |  |  | $ | 991 |  |  | $ | 455 |  |  | $ | 66 |  |  | $ | 3,750 |  |  | $ | 3,817 |
Provisions related to sales made in current year period |  |  | 354 |  |  |  | 4,015 |  |  |  | 654 |  |  |  | 7,579 |  |  |  | 264 |  |  |  | 109 |  |  |  | 12,621 |  |  |  | 12,975 |
Provisions related to sales made in prior periods |  |  | — |  |  |  | (31 | ) |  |  | (33 | ) |  |  | (54 | ) |  |  | 17 |  |  |  | — |  |  |  | (101 | ) |  |  | (101 | )
Credits and payments |  |  | (360 | ) |  |  | (3,974 | ) |  |  | (748 | ) |  |  | (7,662 | ) |  |  | (304 | ) |  |  | (77 | ) |  |  | (12,765 | ) |  |  | (13,125 | )
Translation differences |  |  | — |  |  |  | 18 |  |  |  | 4 |  |  |  | 5 |  |  |  | 4 |  |  |  | (1 | ) |  |  | 30 |  |  |  | 30 |
Balance at December 31, 2023 |  | $ | 61 |  |  | $ | 1,603 |  |  | $ | 540 |  |  | $ | 859 |  |  | $ | 436 |  |  | $ | 97 |  |  | $ | 3,535 |  |  | $ | 3,596 |

X
- Definition Tabular disclosure of sales reserves and allowances current. + References No definition available. + Details
Name: | teva_SalesReservesAndAllowancesCurrentTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration